Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively

Benzinga

01-13

Kiniksa Pharmaceuticals Ltd.2.81%盘前

As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.
Since launch, more than 2,850 prescribers have written ARCALYST prescriptions for recurrent pericarditis.
As of the end of the fourth quarter of 2024, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months.

Corporate Update
As of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments (unaudited).
Kiniksa expects to remain cash flow positive on an annual basis.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

no data

没有相关数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503305031"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503305031\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503305031?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503305031","market":"us","top_or_hot":-1,"title":"Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively","media":"Benzinga","content":"<html><body><ul><li>As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.</li><li>Since launch, more than 2,850 prescribers have written ARCALYST prescriptions for recurrent pericarditis.</li><li>As of the end of the fourth quarter of 2024, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months.       <br/><br/><strong>Corporate Update</strong></li><li>As of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments (unaudited).</li><li>Kiniksa expects to remain cash flow positive on an annual basis.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-01-13 20:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><ul><li>As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.</li><li>Since launch, more than 2,850 prescribers have written ARCALYST prescriptions for recurrent pericarditis.</li><li>As of the end of the fourth quarter of 2024, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months.       <br/><br/><strong>Corporate Update</strong></li><li>As of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments (unaudited).</li><li>Kiniksa expects to remain cash flow positive on an annual basis.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/25/01/42942073/kiniksa-pharmaceuticals-reports-preliminary-q4-and-fy2024-arcalyst-net-product-revenue-of-121-9m-","article_id":"2503305031","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503305031","pubTimestamp":1736772017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.Since launch, more than 2,850 prescribers have written ARCALYST","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"Kiniksa Pharmaceuticals报告第四季度和2024财年Arcalyst产品净收入初步分别为1.219亿美元和4.164亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":0.9},"content_text":"As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.Since launch, more than 2,850 prescribers have written ARCALYST prescriptions for recurrent pericarditis.As of the end of the fourth quarter of 2024, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months.       Corporate UpdateAs of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments (unaudited).Kiniksa expects to remain cash flow positive on an annual basis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}

如果下载按钮点击无跳转，请点击右上角菜单选择 “在浏览器打开”

立即咨询
下载APP
扫码下载APP